{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Carcinoma&page=19", "query": { "condition": "Pancreatic Carcinoma", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 2231, "total_pages": 224, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Carcinoma&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Carcinoma&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T13:04:15.824Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01363232", "title": "Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Selected Solid Tumors" ], "interventions": [ { "name": "BKM120 + MEK162", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Array Biopharma, now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2011-08", "completion_date": "2017-12-18", "has_results": false, "last_update_posted_date": "2020-10-05", "last_synced_at": "2026-10-15T13:04:15.824Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Greenville", "state": "South Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01363232" }, { "nct_id": "NCT03556228", "title": "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Carcinoma", "Adenoid Cystic Carcinoma", "Lung Cancer", "Non-Small Cell Lung Cancer", "Pancreatic Cancer", "Mesothelioma", "Esophageal Cancer", "Any Solid Tumors Progressed After a Prior Immunotherapy", "Head and Neck Squamous Cell Carcinoma", "Head and Neck Squamous Cell Carcinoma HNSCC", "Salivary Gland Carcinomas", "Head and Neck Cancers - Salivary Gland", "Head and Neck Cancers - Nasopharyngeal", "Head and Neck Cancers - Throat", "Small Cell Lung Cancer ( SCLC )", "Lung Cancer (Locally Advanced or Metastatic)", "Head and Neck Cancers - Tonsils", "Head and Neck Cancers Hypopharynx", "Head and Neck Cancers Larynx", "Head and Neck Cancers Lip", "Head and Neck Cancers Nasopharynx", "Head and Neck Cancers Oral Cavity", "Head and Neck Cancers", "Head and Neck Cancers Oropharynx", "Head and Neck Cancers Trachea" ], "interventions": [ { "name": "VMD-928 100 mg Tablet", "type": "DRUG" }, { "name": "VMD-928 Tablet and Pembrolizumab (200 mg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VM Oncology, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 242, "start_date": "2018-06-08", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-10-15T13:04:15.824Z", "location_count": 14, "location_summary": "Santa Rosa, California • Hartford, Connecticut • Washington D.C., District of Columbia + 11 more", "locations": [ { "city": "Santa Rosa", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03556228" }, { "nct_id": "NCT01364805", "title": "New Treatment Option for Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Intravenous Vitamin C", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jeanne Drisko, MD, CNS, FACN", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 14, "start_date": "2011-04", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2018-06-19", "last_synced_at": "2026-10-15T13:04:15.824Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01364805" }, { "nct_id": "NCT02318095", "title": "Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Resectable Pancreatic Cancers" ], "interventions": [ { "name": "Gemcitabine/nab-Paclitaxel", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" }, { "name": "Sugical resection", "type": "OTHER" }, { "name": "Adjuvant chemotheapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2015-02-17", "completion_date": "2022-11-14", "has_results": true, "last_update_posted_date": "2023-10-26", "last_synced_at": "2026-10-15T13:04:15.824Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02318095" }, { "nct_id": "NCT04332653", "title": "NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Any Advanced Solid Tumors", "Triple Negative Breast Cancer", "Non Small Cell Lung Cancer", "Small Cell Lung Cancer", "Microsatellite Stable Colorectal Cancer", "Pancreatic Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "NT-I7", "type": "DRUG" }, { "name": "pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NeoImmuneTech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 215, "start_date": "2020-06-10", "completion_date": "2025-01-13", "has_results": true, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-10-15T13:04:15.824Z", "location_count": 8, "location_summary": "Tampa, Florida • Detroit, Michigan • St Louis, Missouri + 5 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04332653" }, { "nct_id": "NCT07738939", "title": "IKS04 Regimen in Advanced Solid Tumors That Express CA242", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Gastro Esophageal Junctional Cancer", "Gastric Cancer (GC)", "GEJ Adenocarcinoma", "PDAC - Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancer (BTC)", "Gall Bladder Cancer", "Cholangiocarcinoma" ], "interventions": [ { "name": "IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Iksuda Therapeutics Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2026-11", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-15T13:04:15.824Z", "location_count": 4, "location_summary": "Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07738939" }, { "nct_id": "NCT06171945", "title": "Mobile Weight Loss Intervention for Adolescent and Young Adult Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer", "Physical Activity", "Cancer Survivorship", "Mental Health", "Obesity" ], "interventions": [ { "name": "AYA Connect intervention", "type": "BEHAVIORAL" }, { "name": "Positive Psychology (PP) intervention", "type": "BEHAVIORAL" }, { "name": "Positive Psychology Plus (PP+) intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 63, "start_date": "2024-03-01", "completion_date": "2025-10-05", "has_results": false, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-10-15T13:04:15.824Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06171945" }, { "nct_id": "NCT01104129", "title": "Stool Testing for Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreatic Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 158, "start_date": "2009-07-09", "completion_date": "2016-11-29", "has_results": false, "last_update_posted_date": "2021-01-19", "last_synced_at": "2026-10-15T13:04:15.824Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01104129" }, { "nct_id": "NCT01739439", "title": "Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acinar Cell Adenocarcinoma of the Pancreas", "Duct Cell Adenocarcinoma of the Pancreas", "Stage IIB Pancreatic Cancer", "Stage III Pancreatic Cancer" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "hyperfractionated radiation therapy", "type": "RADIATION" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" }, { "name": "radiosurgery", "type": "RADIATION" }, { "name": "diffusion-weighted magnetic resonance imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2013-05", "completion_date": "2015-12-01", "has_results": false, "last_update_posted_date": "2019-07-29", "last_synced_at": "2026-10-15T13:04:15.824Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01739439" }, { "nct_id": "NCT00390182", "title": "Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastrointestinal Neoplasms", "Ovarian Neoplasms" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2003-10", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2020-03-18", "last_synced_at": "2026-10-15T13:04:15.824Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00390182" } ] }